Articles: function.
-
Nocturnal hypoxia, the hallmark of OSA, is a potential contributing factor for nonalcoholic fatty liver disease (NAFLD). NAFLD severity and its implication in OSA-related endothelial dysfunction have not been investigated in a large, unselected OSA population, including nonobese subjects. ⋯ In a large, unselected OSA population, the severity of nocturnal hypoxia was independently associated with steatosis. Preexisting obesity exacerbated the effects of nocturnal hypoxemia. NAFLD is a potential mechanism of endothelial dysfunction in OSA.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Current COPD treatment guidelines recommend long-acting β2-agonist/inhaled corticosteroids (LABA/ICS) for severe COPD patients with a history of exacerbations. The 26-week ILLUMINATE study in moderate-to-severe COPD patients showed superiority of QVA149 versus the LABA/ICS salmeterol/fluticasone combination (SFC) in lung function. A novel study design to evaluate the effect of QVA149 versus SFC on COPD exacerbations in more severe patients with a history of exacerbations is presented. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Nicola Gallagher: Employee: Novartis employee Donald Banerji: Employee: Novartis employee The following authors have nothing to disclose: Jørgen VestboClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA is in the late stage phase 3 trials prior to approval.
-
Telemedicine PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To describe the clinical trial protocol that aims to evaluate the effectiveness of telenursing on lung function in patients with heart failure (HF). ⋯ The following authors have nothing to disclose: Carolina Santos, Bárbara Sueli Moreira, Loyane Alves, Fernanda Mussi, Carolina Souza-MachadoNo Product/Research Disclosure Information.
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Chronic obstructive pulmonary disease (COPD) impacts negatively on the quality of life of patients. Several studies have shown that acute exacerbations (AEs) decrease health-related quality of life, pulmonary function and survival of COPD patients. The objective of the present study was to examine the effects of a physical therapy program on quality of life in COPD patients hospitalized due to an acute exacerbation. ⋯ The following authors have nothing to disclose: Irene Torres-Sánchez, Marie Carmen Valenza, Gerald Valenza-Demet, Irene Cabrera-Martos, María José Flores-Barba, Angela Ruíz-SáezNo Product/Research Disclosure Information.
-
Cardiovascular Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The risk of stroke associated to the various means of cardiac stimulation is still limited and offers only tendencies. It is only known that patients with sinus node dysfunction are in risk of stroke and suggest that ventricular demand pacemakers do not offer protection against this risk. ⋯ The following authors have nothing to disclose: Elieusa Sampaio, Roque Aras Júnior, José Alberto da Matta, Cristiano Macedo, Márcia Maria Oliveira, Ubiratan dos Santos Júnior, Sérgio CâmaraNo Product/Research Disclosure Information.